On August 3, 2026, E Fund Management Co., Ltd. bought 31,000 shares of BIOCYTOGEN-B at an average of HKD 52.6105 per share, involving about HKD 1.63 million.
Prior to the acquisition, E Fund Management Co., Ltd.'s long position in BIOCYTOGEN-B was 11.05 million shares, representing 9.98%; following the acquisition, the holding changed to 11.08 million shares, with the long position ratio rising to 10.0%.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments